<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348504</url>
  </required_header>
  <id_info>
    <org_study_id>3001077</org_study_id>
    <nct_id>NCT00348504</nct_id>
  </id_info>
  <brief_title>Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.</brief_title>
  <official_title>Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the efficacy of levosimendan and dobutamine&#xD;
      on all-cause mortality in the 180 days following randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality in the 180 days following randomization.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality during the 31 days following randomization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in plasma BNP concentration from baseline to 24 hours after the start of the study drug infusion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of day alive and out of hospital (DAOH) during the 180 days following randomization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's evaluation of change in dyspnea at 24 hours following randomization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's evaluation of change in Global Assessment at 24 hours following randomization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality during the 180 days following randomization</measure>
  </secondary_outcome>
  <enrollment>1300</enrollment>
  <condition>Acute Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dobutamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written, signed and dated informed consent&#xD;
&#xD;
          -  Male and female patients over 18 years of age. Females of childbearing potential must&#xD;
             have a negative pregnancy test and must refrain from breastfeeding. Women who are&#xD;
             postmenopausal [two years since last menstrual cycle], surgically sterilised or who&#xD;
             have undergone a hysterectomy are considered not to be of childbearing potential&#xD;
&#xD;
          -  Hospitalised patients with acutely decompensated heart failure&#xD;
&#xD;
          -  Left ventricular ejection fraction less than or equal to 30 % as assessed using&#xD;
             echocardiography, radionuclide ventriculography or contrast angiography within 12&#xD;
             months&#xD;
&#xD;
          -  Clinical need for intravenous inotropic support as evidenced by insufficient response&#xD;
             to intravenous diuretics and/or vasodilators (nitroglycerin, nitroprusside) and at&#xD;
             least one of the following at screening:&#xD;
&#xD;
               -  oliguria (mean urine output &lt; 30 ml/h for at least 6 hours) and not a result of&#xD;
                  hypovolemia&#xD;
&#xD;
               -  dyspnoea at rest or mechanical ventilation for heart failure&#xD;
&#xD;
               -  haemodynamic impairment in those patients with Swan-Ganz catheter inserted (PCWP&#xD;
                  ≥ 18 mmHg and/or Cardiac Index ≤ 2.2 l/min/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe obstruction of ventricular outflow tracts such as haemodynamically significant&#xD;
             uncorrected primary valve disease or hypertrophic cardiomyopathy or impaired&#xD;
             ventricular filling such as restrictive cardiomyopathy&#xD;
&#xD;
          -  Weight ≥ 160 kg&#xD;
&#xD;
          -  Cardiac surgery within 30 days before screening&#xD;
&#xD;
          -  Stroke within 3 months before screening&#xD;
&#xD;
          -  Systolic blood pressure persistently less than 85 mmHg at screening or at baseline&#xD;
&#xD;
          -  Heart rate persistently 130 bpm or greater at screening or at baseline&#xD;
&#xD;
          -  Serum potassium less than 3.5 mmol/l at screening&#xD;
&#xD;
          -  Administration of any inotropic agent (e.g. dobutamine, milrinone, amrinone,&#xD;
             enoximone, epinephrine, norepinephrine) except digitalis or dopamine (with dose of&#xD;
             less than or equal than 2 mg/kg/min) during the current hospitalisation&#xD;
&#xD;
          -  Hypersensitivity to levosimendan or dobutamine or any of their excipients&#xD;
&#xD;
          -  A history of Torsades de Pointes&#xD;
&#xD;
          -  Severe renal insufficiency (serum creatinine &gt; 450 mmol/l [5.0 mg/dl]) or on dialysis&#xD;
&#xD;
          -  Significant hepatic impairment at discretion of the investigator&#xD;
&#xD;
          -  Acute bleeding&#xD;
&#xD;
          -  Severe anemia (haemoglobin &lt; 8 g/dl) at screening&#xD;
&#xD;
          -  Septicaemia or septic shock&#xD;
&#xD;
          -  Other serious diseases limiting life expectancy considerably (e.g. end-stage cancer)&#xD;
&#xD;
          -  Participation in a clinical trial with any experimental treatment within 30 days prior&#xD;
             to screening or previous participation in the present study&#xD;
&#xD;
          -  Administration of levosimendan within 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Padley, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information - Abbott</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>November 16, 2007</last_update_submitted>
  <last_update_submitted_qc>November 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

